Dermira Profile

10.73
USD 0.83  7.18%
69%
21%

Dermira exotic insider transaction detected

Dermira insider trading alert for general transaction of common stock by Thomas Wiggans, CEO & Chairman of the Board, on June 25, 2018. This event was filed by Dermira Inc with SEC on 2018-06-25. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Dermira Summary

Dermira (DERM) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 162 people. Dermira is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 485.86 M. Dermira conducts business under Healthcare sector and is part of Biotechnology industry. This company has 41.85 M outstanding shares of which 3.95 M shares are currently shorted by private and institutional investors with about 4.44 trading days to cover. Dermira currently holds about 495.79 M in cash with (94.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.85 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Dermira Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 10.73HorizonTargetOdds Above 10.73
73.95%30 days 10.73 25.92%
Based on normal probability distribution, the odds of Dermira to move above current price in 30 days from now is about 25.92% (This Dermira probability density function shows the probability of Dermira Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Xact Kapitalforvaltning AbCommon Shares11.5 K106 K
Wellington Management Group LlpCommon Shares5.1 M41 M
View Dermira Diagnostics

Selected Dermira Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Dermira Against Markets

Risk Adjusted
Performance Score (0 to 100)
4 
Chance of
Financial Distress (0 to 100%)
45 
Equity ratings for Dermira are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California. Dermira operates under Biotechnology classification in USA and traded on NASDAQ. It employs 162 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Dermira SEC Filings
Dermira SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameDermira
Chairman of the BoardWilliam YoungView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA U.S.A
Business Address275 Middlefield Road
ExchangeBATS Exchange
CIK Number0001557883
CUSIP24983L104
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.dermira.com
Phone650 421 7200
CurrencyUSD - US Dollar

Dermira Corporate Directors

Jake Nunn Independent Director, CFA
Frederick Craves Independent Director
Matthew Fust Independent Director, MBA
Additionally see Investing Opportunities. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.